Charles River Laboratories (CRL) is a publicly traded diagnostics and research business based in the US. It opened the day at $381.02 after a previous close of $379.2. During the day the price has varied from a low of $379.835 to a high of $384.91. The latest price was $384.89 (25 minute delay). Charles River Laboratories International is listed on the NYSE and employs 20,000 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginners
Best for
Beginner investments
BEST FOR
Transfer bonus
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 - £9.99 | No minimum | £9.19 £1,567.61 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £7.79 £1,566.21 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £15.93 £1,574.35 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £7.79 £1,566.21 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £27.53 £1,585.95 total |
Capital at risk |
 |
★★★★★ | £0 | No minimum | £1.56 £1,559.98 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Charles River Laboratories International P/E ratio, PEG ratio and EBITDA
Charles River Laboratories International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Charles River Laboratories International shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Charles River Laboratories International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1951. A PEG ratio close to 1 can be interpreted as meaning shares offer reasonable value for the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Charles River Laboratories International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $977.2 million (£0.0 million).
The EBITDA is a measure of a Charles River Laboratories International's overall financial performance and is widely used to measure a its profitability.
Join 50,000 subscribers who are notified about expert money tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Nationwide is planning to give eligible members £100 in June as part of its newly launched Fairer Share scheme.
There’s lots to consider when buying cryptocurrency. Here’s your step-by-step guide.
Your kids’ bank account is often where your child starts their financial journey – here’s how we decide our star ratings for them.
We’ve tested, analysed and scored trading apps to find the 10 best trading platforms in the UK, who they’re best for and the pros and cons.
We’ve tested, analysed and scored trading apps to find the 10 best trading platforms in the UK, who they’re best for and the pros and cons.
We’ve tested, analysed and scored trading apps to find the 10 best trading platforms in the UK, who they’re best for and the pros and cons.
Our guide explains all you need to know about the card reader payment process.
Learn more about why you might not have a credit score and why it matters.
We take a closer look at the different fees you face when you get a card machine for your business.
Discover which banks have welcome offers, rewards or refer a friend deals available.